Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A protein puzzle: Untangling the mysterious condition of amyloidosis

A Correction to this article was published on 07 April 2017

This article has been updated

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Change history

  • 23 March 2017

    In the March 2017 issue, the piece “A protein puzzle: Untangling the mysterious condition of amyloidosis” (Nat. Med. 23, 266–269, 2017) incorrectly stated that the FDA placed Ionis’ NEURO-TTR trial on hold. The FDA had placed a related trial called CARDIOTTR on hold after some patients in the NEURO-TTR trial developed complications. The error has been corrected in the HTML and PDF versions of this article.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chakradhar, S. A protein puzzle: Untangling the mysterious condition of amyloidosis. Nat Med 23, 266–269 (2017).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing